QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:KPTI

Karyopharm Therapeutics Stock Forecast, Price & News

$15.60
+0.12 (+0.78 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$15.16
Now: $15.60
$15.82
50-Day Range
$14.20
MA: $15.21
$16.44
52-Week Range
$11.31
Now: $15.60
$29.61
Volume939,609 shs
Average Volume1.59 million shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11
Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIOÃ), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Read More
Karyopharm Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600
Employees347

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.89 million
Book Value$0.79 per share

Profitability

Net Income$-199,590,000.00
Net Margins-228.44%

Miscellaneous

Market Cap$1.15 billion
Next Earnings Date11/2/2020 (Confirmed)
OptionableOptionable
$15.60
+0.12 (+0.78 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

How has Karyopharm Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KPTI stock has decreased by 26.6% and is now trading at $15.60.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Karyopharm Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Karyopharm Therapeutics
.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Karyopharm Therapeutics
.

How can I listen to Karyopharm Therapeutics' earnings call?

Karyopharm Therapeutics will be holding an earnings conference call on Monday, November 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.06. The business earned $33.51 million during the quarter, compared to the consensus estimate of $28.03 million. Karyopharm Therapeutics had a negative return on equity of 186.76% and a negative net margin of 228.44%.
View Karyopharm Therapeutics' earnings history
.

What price target have analysts set for KPTI?

10 brokerages have issued 12 month price objectives for Karyopharm Therapeutics' shares. Their forecasts range from $26.00 to $41.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $33.22 in the next twelve months. This suggests a possible upside of 113.0% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics
.

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), InVitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 57, Pay $942.05k)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Chairman of Scientific Advisory Board (Age 50, Pay $731.01k)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 39, Pay $606.04k)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 59, Pay $106.19k)
  • Mr. Michael P. Mason CPA, Sr. VP, CFO & Treasurer (Age 45)

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.18%), Emerald Mutual Fund Advisers Trust (1.97%), AMI Asset Management Corp (0.83%), Candriam Luxembourg S.C.A. (0.71%), Atlas Private Wealth Advisors (0.06%) and DekaBank Deutsche Girozentrale (0.05%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, John Demaree, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham.
View institutional ownership trends for Karyopharm Therapeutics
.

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Atlas Private Wealth Advisors. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, and Sharon Shacham.
View insider buying and selling activity for Karyopharm Therapeutics
.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was acquired by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, Pacer Advisors Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Karyopharm Therapeutics
.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $15.60.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $1.15 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 347 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.